Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

Modern Pathology

Volumn 29, Issue 2, 2016, Pages 143-156

  Murphy, Stephen J ^a   Karnes, Robert J ^a   Kosari, Farhad ^a   Castellar, B Edgardo R Parilla ^a   Kipp, Benjamin R ^a   Johnson, Sarah H ^a   Terra, Simone ^a   Harris, Faye R ^a   Halling, Geoffrey C ^a   Klein, Janet L Schaefer ^a   Nasir, Aqsa ^a   Bergstrahl, Eric ^a   Rangel, Laureano J ^a   Sukov, William R ^a   Vasmatzis, George ^a   Cheville, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ONCOPROTEIN; PTEN PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER CELL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOME ANALYSIS; GENOMIC INSTABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; POINT MUTATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEPLETION; PROTEIN EXPRESSION; CANCER GRADING; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; GENE FUSION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; DNA MUTATIONAL ANALYSIS; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PHENOTYPE; POINT MUTATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84956632580     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.136     Document Type: Article

References (41)

1. Cairns P, Okami K, Halachmi S et al. Frequent inactivation of PTEN/MMAC in primary prostate cancer. Cancer Res 1997;57:4997-5000.
2. Feilotter HE, Nagai MA, Boag AH et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-1782.
3. Pesche S, Latil A, Muzeau F et al. PTEN/MMAC/TEP1 involvement in primary prostate cancers. Oncogene 1998;16:2879-2883.
4. Suzuki H, Freije D, Nusskern DR et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple prostate cancer tissues. Cancer Res 1998;58:204-209.
5. Wang SI, Parsons R, Ittmann M. Homozygous deletion of PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-815.
6. Whang YE, Wu X, Suzuki H et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246-5250.
7. Han B, Mehra R, Lonigro RJ et al. Fluorescence in situ hybridization study shows association of PTEN deletion and ERG rearrangement during prostate cancer progression. Mod Pathol 2009;22:1083-1093.
8. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
9. Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-685.
10. Yoshimoto M, Cutz JC, Nuin PA et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006;169:128-137.
11. Suzuki H, Freije D, Nusskern DR et al. Interfocal heterogeneity of PTEN/MMAC gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-209.
12. Krohn A, Diedler T, Burkhardt L et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012;181:401-412.
13. McCall P, Witton CJ, Grimsley S et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer 2008;99:1296-1301.
14. Sircar K, Yoshimoto M, Monzon FA et al. PTEN genomic deletion is associated with p-AKT and AR signaling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;218:678-684.
15. Yoshimoto M, Joshua AM, Cunha IW et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21(12):1451-1460.
16. Reid AH, Attard G, Ambroisine L et al. Molecular characterization of ERG, ETV1, and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010;102:678-684.
17. Bismar TA, Yoshimoto M, Vollmer R et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Intl 2010;107:4077-4485.
18. Di Cristofano A, Pesce B, Cordon-Cardo C et al. PTEN is essential for embryonic development and tumor suppression. Nat Genet 1998;19:348-355.
19. Di Cristofano A, De Acetis M, Koff A et al. PTEN and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Gen 2001;27:222-224.
20. Kwabi-Addo B, Giri D, Schmidt K et al. Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-11568.
21. Luchman HA, Benediktsson H, Villemaire AC et al. The pace of prostatic intraepithelial neoplasia development is determined by the timing of PTEN tumor suppressor gene excision. PloS One 2008;3:3940.
22. McMenamin ME, Soung P, Perera S et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-4296.
23. Lotan TL, Gumuskaya B, Rahimi H et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol 2012;26:587-603.
24. Ross HM, Kryvenko ON, Cowan JE et al. Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346-1152.
25. Lotan TL, Carvalho FL, Peskoe SB et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2015;28:128-137.
26. Sebo TJ, Cheville JC, Riehle DL et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002;26:7-14.
27. Murphy SJ, Cheville JC, Zarei S et al. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res 2012;19:395-406.
28. Kovtun IV, Cheville JC, Murphy SJ et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res 2013;73:3275-3284.
29. Kovtun IR, Murphy SJ, Johnson SH et al. Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer. Oncotarget 2015;6:29087-29096.
30. Murphy SJ, Hart SN, Lima JF et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013;145:1098-1109.
31. Vasmatzis G, Johnson SH, Knudson RA et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012;120:2280-2289.
32. Drucker TM, Johnson SH, Murphy SJ et al. BIMA V3: an aligner customized for mate pair library sequencing. Bioinformatics 2014;30:1627-1629.
33. Lotan TL, Gurei B, Sutcliffe S et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2013;17:6563-6573.
34. Reid AHM, Attard G, Brewer D et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012;25:902-910.
35. Konishi N, Nakamura M, Kishi M et al. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002;160:1207-1214.
36. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
37. Carver BS, Tran J, Gopalan A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-624.
38. Alimonti A, Carracedo A, Clohessy JG et al. Subtle variations in PTEN dose determine cancer susceptibility. Nat Genet 2010;42:454-458.
39. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 2009;41:509-510.
40. Yoshimoto M, Ding K, Sweet JM et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2012;26:435-447.
41. Shah RB, Bentley J, Jeffery Z et al. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. Hum Pathol. 2015;46:698-706.